Nanobiotix (NBTX)

Currency in USD
37.79
+0.26(+0.69%)
Closed·
37.790.00(0.00%)
·
Unusual trading volume
NBTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
36.1238.38
52 wk Range
4.9357.14
Key Statistics
Prev. Close
37.53
Open
36.16
Day's Range
36.12-38.38
52 wk Range
4.93-57.14
Volume
218.73K
Average Volume (3m)
89.5K
1-Year Change
619.8095%
Book Value / Share
-2.05
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NBTX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
43.84
Upside
+16.01%
Members' Sentiments
Bearish
Bullish
ProTips
High return over the last year

Nanobiotix News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

5 Buy
2 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 43.84
(+16.01% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Leerink
Buy46.00+21.73%37.00MaintainJun 04, 2026
UBS
Hold30.00-20.61%3.50MaintainMay 01, 2026
Guggenheim
Buy36.00-4.74%26.00MaintainApr 02, 2026
Leerink Partners
Buy37.00-2.09%26.00MaintainApr 01, 2026
TD Cowen
Buy---MaintainMar 12, 2026

Nanobiotix Earnings Call Summary for H2/2025

  • Nanobiotix cut FY 2025 net loss to €24M from €68.1M, aided by amended J&J licensing deal and 43% R&D expense reduction
  • Company missed EPS forecast at -0.5069 vs -0.3943 expected; revenue reached €32.6M driven by one-time accounting impact
  • Stock rose 3.47% to $31.94 in premarket despite EPS miss; shares gained 762% over past year with $1.49B market cap
  • Cash position of €52.8M extends runway into early 2028; projects EPS of -0.34 for FY2025 and -0.24 for FY2026
  • Strategic focus on NBTXR3 oncology product and capital-efficient development; anticipates milestone payments from Janssen partnership
Last Updated: 2026-04-01, 09:20 a/m
Read Full Transcript

Earnings

Latest Release
May 29, 2026
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

NBTX Income Statement

Compare NBTX to Peers and Sector

Metrics to compare
NBTX
Peers
Sector
Relationship
P/E Ratio
−69.8x−2.8x−0.4x
PEG Ratio
−1.07−0.020.00
Price/Book
−19.8x0.9x2.6x
Price / LTM Sales
51.3x16.1x3.0x
Upside (Analyst Target)
5.9%262.6%50.8%
Fair Value Upside
Unlock4.4%9.4%Unlock

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
2.76M5.68%104.21M
Other Institutional Investors
26.01M53.59%982.81M
Public Companies & Retail Investors
19.76M40.73%746.90M
Total
48.53M100.00%1.83B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Invus Public Equities, L.P.12.04%5,844,592220,867
Artal Group S.A.12.04%5,844,592220,867

People Also Watch

87.34
SOIT
-3.15%
19.170
ERAS
+0.79%
32.96
NANOB
-1.55%
68.24
LGN
-1.29%
100.35
ATEX
+6.79%

FAQ

What Is the Nanobiotix (NBTX) Stock Price Today?

The Nanobiotix stock price today is 37.79 USD.

What Stock Exchange Does Nanobiotix Trade On?

Nanobiotix is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Nanobiotix?

The stock symbol for Nanobiotix is "NBTX."

What Is the Nanobiotix Market Cap?

As of today, Nanobiotix market cap is 1.91B USD.

What Is Nanobiotix's Earnings Per Share (TTM)?

The Nanobiotix EPS (TTM) is -0.50.

When Is the Next Nanobiotix Earnings Date?

Nanobiotix will release its next earnings report on Sep 30, 2026.

From a Technical Analysis Perspective, Is NBTX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Nanobiotix Stock Split?

Nanobiotix has split 0 times.

How Many Employees Does Nanobiotix Have?

Nanobiotix has 100 employees.

What is the current trading status of Nanobiotix (NBTX)?

As of Jul 18, 2026, Nanobiotix (NBTX) is trading at a price of 37.79 USD, with a previous close of 37.53 USD. The stock has fluctuated within a day range of 36.12 USD to 38.38 USD, while its 52-week range spans from 4.93 USD to 57.14 USD.

What Is Nanobiotix (NBTX) Price Target According to Analysts?

The average 12-month price target for Nanobiotix is 43.84 USD, with a high estimate of 69.11118737 USD and a low estimate of 29.26103866 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +16.01% Upside potential.

What Is the NBTX Premarket Price?

NBTX's last pre-market stock price is 36.36 USD. The pre-market share volume is 910.00, and the stock has decreased by -1.17, or -3.12%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.